1. China Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Shanghai Model Organisms Center, Inc. Class A

Shanghai Model Organisms Center, Inc. Class A

SSSE:688265
48.65
CNY
+0.02
(+0.04%)
0.45EPS
77.64P/E
2.70BMarket Cap
Oct 30Next Earn
Shanghai Model Organisms Center, Inc. Class A
SSE:688265
(Shanghai Stock Exchange)

Recent

price

48.65

P/E

ratio

77.64

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.68
5.14
6.21
1.47
2.33
2.93
3.43
4.7
3.93
4.63
4.7
5.62
6.21
Revenue per Share
0.49
1.2
1.5
-0.31
0.29
0.44
0.78
1.04
-0.07
-0.26
0.08
0.42
0.45
Basic EPS, GAAP
1
1.94
-0.13
-0.71
0.18
0.62
-0.77
1.01
-3.26
-1.32
0.57
0.69
- -
Free Cash Flow per Basic Share
1.24
0.14
- -
- -
- -
- -
- -
- -
0.27
0.01
0.12
- -
- -
Dividend per Share
0.65
3.46
4.29
5.53
2.13
2.57
4.36
22.88
22.65
22.28
21.59
21.92
22.03
Book Value per Share
0.35
3.16
4.29
5.53
2.13
2.57
4.36
22.87
19.51
19.13
18.49
18.9
19.06
Tangible Book Value per Share
19
9
10
52
52
53
57
59
77
79
81
75
74
Basic Weighted Avg Shares
33
45
61
76
121
155
196
275
303
367
381
421
458
Sales/Revenue/Turnover
30.78
21.13
22.45
-19.72
9.16
14.7
25.11
24.64
-9.3
-8.65
-2.86
5.89
7.02
Operating Margin (%)
1
1
1
3
7
7
7
17
37
48
60
55
- -
Depreciation Expense
10
11
15
-16
15
23
45
61
-5
-21
6
31
33
Net Income, GAAP
10.83
10.74
12.8
- -
5.47
4.46
8.84
11.89
- -
- -
- -
- -
- -
Effective Tax Rate (%)
29.13
23.34
24.16
-21.04
12.44
15.02
22.71
22.11
-1.78
-5.62
1.7
7.47
7.18
Profit Margin (%)
3
51
68
40
61
93
123
1,617
1,092
986
973
965
897
Working Capital
- -
- -
- -
- -
- -
- -
29
26
107
69
53
41
38
LT Debt
11
61
75
97
112
135
255
1,784
1,766
1,737
1,683
1,709
1,718
Total Equity
- -
25.33
18.54
- -
14.65
17.98
21.69
5.73
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
29.43
21.51
- -
14.45
18.79
21.25
5.94
- -
- -
- -
- -
- -
Return on Capital (%)
- -
29.43
21.51
-18.63
14.45
18.79
22.83
5.97
-0.3
-1.18
0.38
1.85
1.93
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16
16
15
LT Borrowings
- -
- -
- -
LT Finance Leases
41
43
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
3,197
3,199
2,697

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,181
1,111
1,119
Cash, Cash Equivalents & STI
1,034
932
900
Accounts Receivable, Net
112
133
165
Inventories
19
27
34
Total Current Liabilities
216
190
222
Payables & Accruals
- -
- -
- -
ST Debt
16
16
15
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
77.3%
119.1%
1.56%
Free Cash Flow
167.23%
-190.46%
10.75%
Net Income, GAAP
24.09%
92.26%
383.97%
Sales/Revenue/Turnover
25.86%
17.16%
10.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
83
94
88
116
381
2025
88
107
- -
118
421
2026
100
133
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
0.05
-0.08
0.29
0.08
2025
-0.01
0.25
- -
0.06
0.42
2026
0.01
0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.12
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Shanghai Model Organisms Center, Inc. (688265:SHH) engages primarily in research, development, production, sale, and technical services for genetically modified animal models utilized in life sciences research and drug discovery, particularly for cancer immunotherapy and gene function studies. The company specializes in model organisms including mice, rats, zebrafish, and nematodes, employing gene editing technologies such as CRISPR and ES cell targeting to create customized and standardized models; its core offerings encompass toolbox mice, disease models for rare, infectious, nervous system disorders, and spontaneous tumors, target humanized knock-ins covering tumor targets, immune checkpoints, complements, cytokines, metabolic pathways, and viral infection receptors, immunodeficient and reporter strains, cell models including reporter-labeled and primary cells, as well as supporting services like model breeding, colony management with cryopreservation and cryorecovery, housing, genotyping analysis, phenotypic evaluation, non-GLP toxicology, pharmacokinetics, and auxiliary apparatuses such as e-BLOT Western blot imaging systems. Founded in September 2000 and headquartered in Pudong New District, Shanghai, China, the company operates mainly in the biotechnology sector, serving universities, research institutes, hospitals, and pharmaceutical firms globally with a library exceeding 6,000 off-the-shelf mouse models and over 11,000 prototypes; it maintains 731 employees and reported trailing twelve-month revenue of CNY 400.15 million. Recent developments include a five-year global collaboration agreement with Crown Bioscience announced in May 2024, extending prior ties to supply genetically engineered mouse models, cell line development, and custom GEMM models worldwide, alongside uniform pricing and IP protections; additionally, the company secured U.S. NIH Office of Laboratory Animal Welfare approval for its animal facility in January 2021 and continues expanding preclinical immuno-oncology capabilities.